Skip to main content
TipRanks
Go Ultimate75% OFF

Takeda Pharmaceutical Company (TAK) Revenue by Segment

1,372 Followers

Revenue by Segment

In Q2 FY2026, Takeda Pharmaceutical Company reported revenue by segment of ¥385.80B (GI), ¥194.00B (Rare Disease), ¥273.10B (Plasma-Derived Therapies), ¥148.80B (Oncology), ¥108.40B (Neuroscience) and ¥23.30B (Vaccines).

Analyzes income from different business units, highlighting which segments drive growth and profitability, and indicating areas of strategic focus or potential vulnerability.

¥0.00¥250.00B¥500.00B¥750.00B¥1.00T¥1.25TMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25
Chart Insights

Takeda's revenue from Plasma-Derived Therapies and Oncology segments shows robust growth, reflecting strategic focus and successful product launches. However, Neuroscience revenue is declining, likely impacted by the loss of exclusivity for VYVANSE, which caused a significant revenue drop. The earnings call highlights a mixed outlook with currency headwinds and impairment losses affecting profitability, yet optimism remains for H2 due to anticipated growth in launch products and strategic partnerships, particularly in oncology. Investors should watch for recovery in Neuroscience and potential upside from new pipeline advancements.

No longer reported by the company (last reported Q2 FY2026)

TAK Revenue by Segment

PeriodGIRare DiseasePlasma-Derived TherapiesOncologyNeuroscienceVaccinesOthers
Q2 FY2026Sep 30, 2025¥385.80B¥194.00B¥273.10B¥148.80B¥108.40B¥23.30B¥58.30B
Q1 FY2026Jun 30, 2025¥353.50B¥184.10B¥256.60B¥149.10B¥97.50B¥20.20B¥51.90B
Q4 FY2025Mar 31, 2025¥339.30B¥196.40B¥260.90B¥138.80B¥108.60B¥11.50B¥51.20B
Q3 FY2025Dec 31, 2024¥317.70B¥173.80B¥248.50B¥132.00B¥109.30B¥5.50B¥66.50B
Q2 FY2025Sep 30, 2024¥344.10B¥190.40B¥248.50B¥143.40B¥141.90B¥11.80B¥64.00B
Q1 FY2025Jun 30, 2024¥346.70B¥189.20B¥264.20B¥142.90B¥145.50B¥25.60B¥61.90B
Q4 FY2024Mar 31, 2024¥348.50B¥199.50B¥271.40B¥142.10B¥169.10B¥12.50B¥64.90B
Q3 FY2024Dec 31, 2023¥280.20B¥164.10B¥229.20B¥116.10B¥152.10B¥20.80B¥88.30B
Q2 FY2024Sep 30, 2023¥339.20B¥183.40B¥244.30B¥121.10B¥144.20B¥11.70B¥67.30B
Q1 FY2024Jun 30, 2023¥303.30B¥170.10B¥221.00B¥114.70B¥153.70B¥7.30B¥73.10B
Q4 FY2023Mar 31, 2023¥293.50B¥170.80B¥209.20B¥110.50B¥177.00B¥10.50B¥87.00B
Q3 FY2023Dec 31, 2022¥237.00B¥169.80B¥0.00¥93.80B¥160.60B¥0.00¥118.90B
Q2 FY2023Sep 30, 2022¥311.10B¥191.40B¥0.00¥119.70B¥174.80B¥0.00¥111.10B
Q1 FY2023Jun 30, 2022¥276.00B¥180.60B¥0.00¥107.80B¥159.90B¥0.00¥105.90B
Q4 FY2022Mar 31, 2022¥270.40B¥181.60B¥0.00¥117.50B¥142.40B¥0.00¥118.70B
Q3 FY2022Dec 31, 2021¥210.00B¥148.30B¥0.00¥109.60B¥119.70B¥0.00¥142.00B
Q2 FY2022Sep 30, 2021¥236.60B¥162.80B¥0.00¥125.40B¥128.90B¥0.00¥122.30B
Q1 FY2022Jun 30, 2021¥218.60B¥144.60B¥0.00¥112.30B¥120.30B¥0.00¥118.20B
Q4 FY2021Mar 31, 2021¥210.50B¥155.50B¥0.00¥121.40B¥113.40B¥0.00¥241.60B
Q3 FY2021Dec 31, 2020¥189.00B¥145.00B¥0.00¥98.00B¥102.20B¥0.00¥128.70B
Q2 FY2021Sep 30, 2020¥209.00B¥151.30B¥0.00¥108.40B¥107.30B¥0.00¥153.50B
Q1 FY2021Jun 30, 2020¥192.90B¥140.40B¥0.00¥102.10B¥100.90B¥0.00¥152.00B
Q4 FY2020Mar 31, 2020¥186.90B¥155.00B¥0.00¥108.00B¥106.90B¥0.00¥139.80B

Related KPIs